GlucoTec, a parent company of Glytec, has completed a Series A preferred stock financing of amount $8,273,078.

The fund will be used by Glytec to advance research and development, increase its international presence and diverse its direct US sales force.

Glytec develops real-time glycemic management systems for individualized dosage recommendations of insulin, glucose and saline.

The company will also consider all pertinent patient information such as demographics, lab results, and risk factors.